Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Completed · Phase 1/Phase 2
Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining chemotherapy and monoclonal antibody therapy in treating patients who have advanced myeloid cancer.
Key facts
- Study ID
- NCT00014495
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 32
- Starts
- 2000-11-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2016-01-22
Who can join
Age: any, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan - Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.